Amgen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

17.04.18	Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment Failures (PR Newswire)
17.04.18	Linguamatics Spring Text Mining Conference 2018 to Feature Speakers from Leading Biomedical Organizations (PR Newswire)
10.04.18	Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant (PR Newswire)
09.04.18	Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018 (PR Newswire)
04.04.18	Karma Automotive To Debut New TV Spot During CBS Coverage Of The 2018 Masters Golf Tournament® (PR Newswire)
03.04.18	Amgen: European Commission Approves Expanded Indication For XGEVA - Quick Facts (RTTNews)
03.04.18	European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma (PR Newswire)
02.04.18	Protein-Packed Muuna® Is Now Powered by Popular 2018 Food Trend - Probiotics (PR Newswire)
29.03.18	FDA Approves Amgen's Supplemental Biologics License Application For Blincyto (RTTNews)
29.03.18	FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children (PR Newswire)
25.03.18	An Ear To The Pharma: 5 Stocks To Watch This Week (RTTNews)
23.03.18	Amgen, Allergan: CHMP Adopts Positive Opinion For ABP 980 - Quick Facts (RTTNews)
23.03.18	Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes (PR Newswire)
23.03.18	Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer (PR Newswire)
17.03.18	QUANTUM CORPORATION SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Quantum Corporation - QTM (PR Newswire)
09.03.18	New Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events (PR Newswire)
08.03.18	Amgen Announces Final Results Of Tender Offer (PR Newswire)
07.03.18	Amgen Announces 2018 Second Quarter Dividend (PR Newswire)
07.03.18	Amgen To Present At the Cowen and Company 38th Annual Health Care Conference (PR Newswire)
04.03.18	An Ear To The Pharma: 7 Stocks To Watch This Week (RTTNews)
27.02.18	Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta® (pegfilgrastim) (PR Newswire)
27.02.18	Biotech Stocks Facing FDA Decision In March (RTTNews)
26.02.18	Amgen To Present New Data From Repatha® (evolocumab) Clinical Trials At ACC.18 (PR Newswire)
23.02.18	Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe (PR Newswire)
14.02.18	Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab) (PR Newswire)
09.02.18	Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology (PR Newswire)
08.02.18	Amgen To Present At The 7th Annual Leerink Partners Global Healthcare Conference (PR Newswire)
06.02.18	Acclaimed Hollywood Film Director And Arkansas Native, LazRael Lison, Gives Back With Scholarships For Local High School Seniors (PR Newswire)
01.02.18	EARNINGS SUMMARY: Details of Amgen Inc. Q4 Earnings Report (RTTNews)
01.02.18	Amgen Reports Fourth Quarter And Full Year 2017 Financial Results (PR Newswire)
30.01.18	Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label (PR Newswire)
29.01.18	Amgen Announces Webcast of 2017 Fourth Quarter and Full Year Financial Results (PR Newswire)
24.01.18	MGM Resorts Named One of 'World's Most Admired Companies' (PR Newswire)
23.01.18	AMGN's LIBERTY Meets Goals, ANTH Yields RESULT, CCXI Up On Cancer Trial Data (RTTNews)
22.01.18	Novartis: Erenumab Meets All Endpoints In LIBERTY Migraine Prevention Trial (RTTNews)
22.01.18	Amgen Reports Aimovig™ (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments (PR Newswire)
22.01.18	Some Branded Drugs Going Generic In 2018 (RTTNews)
19.01.18	Amgen And Allergan's MVASI Gets EU Approval To Treat Certain Types Of Cancer (RTTNews)
18.01.18	European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer (PR Newswire)
18.01.18	incredibles, Colorado's Compliance-Focused And Patient-Driven Cannabis Brand, Forges Strategic Partnerships With Like-Minded Partners To Deliver Products To Florida, Illinois And Oregon (PR Newswire)
17.01.18	FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label (PR Newswire)
17.01.18	Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology (PR Newswire)
09.01.18	Human Longevity, Inc. and AMRA Partner to Provide Advanced Body Composition Profiling to HLI's Health Nucleus Clients (PR Newswire)
09.01.18	Seek Thermal Debuts First High-Resolution Thermal Imaging Camera Designed for Automotive Aftermarket and Priced Under $999 at CES 2018 (PR Newswire)
09.01.18	Belgium's Biocartis, Amgen In Deal To Develop Idylla CDx Biomarker Tests (RTTNews)
08.01.18	Amgen Says EMA Accepts Filing For EVENITY Application (RTTNews)
08.01.18	European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab) (PR Newswire)
05.01.18	Amgen Says FDA Approves SBLA For XGEVA (RTTNews)
05.01.18	FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma (PR Newswire)
16.12.17	Centene's Washington Subsidiary Reaches agreement with State of Washington (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

19.11.24		Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein
19.11.24		Zurückhaltung in Frankfurt: SDAX beendet die Dienstagssitzung mit Verlusten
19.11.24		Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer
19.11.24		Schwacher Handel in Frankfurt: TecDAX schwächelt zum Handelsende
19.11.24		Schwacher Handel: SDAX fällt nachmittags
19.11.24		Minuszeichen in Frankfurt: TecDAX verbucht nachmittags Verluste
19.11.24		Bayer expandiert: Japan-Lizenz für potenzielles Herzmedikamentenkandidaten gesichert - Aktie tiefer
19.11.24		Dienstagshandel in Frankfurt: TecDAX präsentiert sich mittags leichter

19.11.24

Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein

19.11.24

Zurückhaltung in Frankfurt: SDAX beendet die Dienstagssitzung mit Verlusten

19.11.24

Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer

19.11.24

Schwacher Handel in Frankfurt: TecDAX schwächelt zum Handelsende

19.11.24

Schwacher Handel: SDAX fällt nachmittags

19.11.24

Minuszeichen in Frankfurt: TecDAX verbucht nachmittags Verluste

19.11.24

Bayer expandiert: Japan-Lizenz für potenzielles Herzmedikamentenkandidaten gesichert - Aktie tiefer

19.11.24

Dienstagshandel in Frankfurt: TecDAX präsentiert sich mittags leichter

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

Nachrichten zu Amgen Inc.

Aktien Top/Flop

Amgen Peer Group Nachrichten

Meistgelesene Nachrichten